Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Implications of pharmacogenomics for drug development and clinical practice.

Publication ,  Journal Article
Ginsburg, GS; Konstance, RP; Allsbrook, JS; Schulman, KA
Published in: Arch Intern Med
November 14, 2005

Pharmacogenomics is likely to be among the first clinical applications of the Human Genome Project and is certain to have an enormous impact on the clinical practice of medicine. Herein, we discuss the potential implications of pharmacogenomics on the drug development process, including drug safety, productivity, market segmentation, market expansion, differentiation, and personalized health care. We also review 3 challenges facing the translation of pharmacogenomics into clinical practice: dependence on information technology, limited health care financing, and the scientific uncertainty surrounding validation of specific applications of the technology. To our knowledge, there is currently no formal agenda to promote and cultivate innovation, to develop progressive information technology, or to obtain the financing that would be required to advance the use of pharmacogenomic technologies in patient care. Although the potential of these technologies is driving change in the development of clinical sciences, it remains to be seen which health care systems level needs will be addressed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arch Intern Med

DOI

ISSN

0003-9926

Publication Date

November 14, 2005

Volume

165

Issue

20

Start / End Page

2331 / 2336

Location

United States

Related Subject Headings

  • United States
  • Technology, Pharmaceutical
  • Pharmacogenetics
  • Personal Health Services
  • Marketing of Health Services
  • Humans
  • General & Internal Medicine
  • Efficiency
  • Drug-Related Side Effects and Adverse Reactions
  • Drug Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., & Schulman, K. A. (2005). Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med, 165(20), 2331–2336. https://doi.org/10.1001/archinte.165.20.2331
Ginsburg, Geoffrey S., Richard P. Konstance, Jennifer S. Allsbrook, and Kevin A. Schulman. “Implications of pharmacogenomics for drug development and clinical practice.Arch Intern Med 165, no. 20 (November 14, 2005): 2331–36. https://doi.org/10.1001/archinte.165.20.2331.
Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med. 2005 Nov 14;165(20):2331–6.
Ginsburg, Geoffrey S., et al. “Implications of pharmacogenomics for drug development and clinical practice.Arch Intern Med, vol. 165, no. 20, Nov. 2005, pp. 2331–36. Pubmed, doi:10.1001/archinte.165.20.2331.
Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med. 2005 Nov 14;165(20):2331–2336.

Published In

Arch Intern Med

DOI

ISSN

0003-9926

Publication Date

November 14, 2005

Volume

165

Issue

20

Start / End Page

2331 / 2336

Location

United States

Related Subject Headings

  • United States
  • Technology, Pharmaceutical
  • Pharmacogenetics
  • Personal Health Services
  • Marketing of Health Services
  • Humans
  • General & Internal Medicine
  • Efficiency
  • Drug-Related Side Effects and Adverse Reactions
  • Drug Therapy